- RecruitingPHASE2
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
This study looks at a new drug, OMS906, for a rare blood condition called Paroxysmal Nocturnal Hemoglobinuria (PNH). It checks how safe it is, if people can tolerate it, and if it helps over a long time. Patients get the drug through an IV every eight weeks.
For: Paroxysmal Nocturnal HemoglobinuriaGermany · Switzerland · Ukraine - RecruitingPHASE2
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
This study is testing a new drug, OMS906, for adults with two rare kidney diseases: C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN). We want to see how safe it is and if it helps improve their condition.
For: C3 Glomerulopathy · Idiopathic Immune Complex-Mediated GlomerulonephritisLithuania · New Zealand · Poland